Chinese maker of animal-tissue heart valves, congenital heart disease implants and soft-tissue repair products.
Chinese maker of animal-tissue heart valves, congenital heart disease implants and soft-tissue repair products.
Sells implants made from treated animal tissue, mainly artificial heart valves from cow-heart-sac membrane or pig aorta, plus implants for children with congenital heart defects, to hospitals. Surgeons choose by clinical record, and prices follow hospital procurement rules. It is extending the tissue-treatment know-how into soft-tissue and collagen products.
Moat: narrow (IP / patents, regulatory licence). Animal-tissue treatment know-how (anti-rejection, anti-calcification) and device approvals; surgeons' familiarity with the valves.
Headquarters: Beijing, China · Employees: 746
Size Beijing Balance Medical Technology (688198.SS) is a China Health Care company (Medical Specialties) with a market value of $1.31B, the 1719th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥64.13 on 18 Nov 2026.
Performance Over six months the shares fell 31.9%, against -10.2% for the median peer and -20.0% for the China market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 10.4% over the last twelve months (peer median +7.3%); the operating margin is 28.3% (peer median 6.7%).
Valuation It trades at 41.5× forward earnings against a peer median of 22.9× (5th most expensive of 17).
Price implies For today's price to make sense, revenue must grow about 21% a year for seven years (Req g). Recent delivered growth is +28%, so the hurdle is -7 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.2 points above its cost of capital (6.4% WACC).
Next results Next results expected around 22 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥653M | CN¥614M | CN¥500M | CN¥370M | CN¥294M |
| Revenue growth | — | +23% | +35% | +26% | — |
| Gross profit | CN¥593M | CN¥509M | CN¥419M | CN¥319M | CN¥258M |
| EBITDA | n/a | CN¥230M | CN¥156M | CN¥113M | CN¥88.8M |
| Net income | CN¥177M | CN¥194M | CN¥146M | CN¥115M | CN¥95.1M |
| Free cash flow | CN¥17.0M | CN¥72.6M | -CN¥13.8M | CN¥25.7M | CN¥42.9M |
| Capital expenditure | CN¥125M | CN¥136M | CN¥163M | CN¥129M | CN¥105M |
| Total debt | CN¥194M | CN¥93.6M | CN¥9.79M | CN¥12.3M | CN¥1.40M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Beijing Balance Medical Technology 688198.SS | $1.31B | -32% | +10% | 28% | 41.5× | 20.7% |
| Edwards Lifesciences EW | $60.5B | +27% | +13% | 29% | 32.3× | 17.1% |
| Medtronic MDT | $129B | +30% | +10% | 20% | 16.8× | 9.1% |
| LifeTech Scientific 1302.HK | $771M | -30% | +1% | 12% | 19.8× | 9.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688198.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -8.9% | -0.9% | 5th lowest of 21 |
| 6-month return | -31.9% | -10.2% | 3rd lowest of 21 |
| Distance from 52-week high | -51.8% | -32.6% | 3rd lowest of 21 |
| Revenue growth (TTM) | +10.4% | +7.3% | 10th highest of 20 |
| Operating margin | 28.3% | 6.7% | 4th highest of 20 |
| Forward P/E | 41.5× | 22.9× | 5th most expensive of 17 |
| Growth the price implies (Req g, 7 yrs) | 20.7% | 10.3% | 4th most demanding of 14 |
| Growth delivered (Del g) | +27.6% | +9.9% | 2nd highest of 14 |
| Hurdle (Req g minus delivered) | -6.9 pp | -6.8 pp | 7th least demanding of 14 |
| ROIC minus cost of capital | +8.2 pp | +0.2 pp | 5th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Beijing Balance Medical Technology 688198.SS | China | $1.31B | -32% | +10% | 28% | 41.5× | 20.7% | +27.6% |
| Suzhou Sepax Technologies 688758.SS | China | $1.31B | +8% | +28% | 40% | 46.0× | 22.8% | +23.6% |
| Sonoscape Medical 300633.SZ | China | $1.31B | -10% | +18% | 4% | 34.7× | n/a | n/a |
| Ovctek China 300595.SZ | China | $1.33B | -25% | 0% | 28% | 19.4× | 8.3% | +16.5% |
| STAAR Surgical STAA | United States | $1.27B | -23% | +42% | 7% | 46.9× | 35.1% | +7.9% |
| NovoCure NVCR | United States | $1.25B | -40% | +13% | -17% | n/a | n/a | n/a |
| Sansure Biotech 688289.SS | China | $1.24B | -17% | -1% | 1% | 35.6× | n/a | n/a |
| Eyebright Medical Technology (Beijing) 688050.SS | China | $1.21B | -16% | +21% | 16% | 23.9× | 10.3% | +40.3% |
| Shenzhen Edge Medical 2675.HK | Hong Kong | $1.21B | -51% | +132% | 2% | 120.2× | n/a | n/a |
| CONMED CNMD | United States | $1.43B | +30% | +2% | 2% | 10.4× | 31.6% | +9.8% |
| Tandem Diabetes Care TNDM | United States | $1.19B | +13% | +7% | -2% | n/a | n/a | n/a |
| PROCEPT BioRobotics PRCT | United States | $1.45B | -10% | +17% | -34% | n/a | n/a | n/a |
| Sinocare 300298.SZ | China | $1.45B | +4% | +7% | 6% | 21.5× | 9.5% | +18.3% |
| Inner Mongolia Furui Medical Science 300049.SZ | China | $1.45B | -31% | +11% | 25% | 41.9× | 2.9% | +14.6% |
| El.En ELN.MI | Italy | $1.46B | +11% | +3% | 15% | 22.0× | 10.7% | +7.7% |
| Shandong Weigao Orthopaedic Device 688161.SS | China | $1.14B | -29% | -6% | 18% | 24.9× | 11.3% | -3.5% |
| Beijing Strong Biotechnologies 300406.SZ | China | $1.13B | -4% | -4% | 36% | 18.2× | 1.7% | +9.9% |
| Shanghai MicroPort Endovascular MedTech 688016.SS | China | $1.55B | -19% | +16% | 44% | 16.4× | 2.7% | +23.4% |
| Alpha Tau Medical DRTS | United States | $1.11B | +7% | n/a | n/a | n/a | n/a | n/a |
| Nihon Kohden 6849.T | Japan | $1.55B | +3% | 0% | 7% | 18.8× | -3.5% | +3.3% |
| Enovis ENOV | United States | $1.56B | +2% | +3% | 4% | 7.6× | 20.0% | -6.0% |